Volume 52, Number 7
July 2023

Direct oral anticoagulants (DOACs) are prescribed for conditions such as stroke, but they are associated with bleeding complications.

A study investigated the association between polymorphisms in fibrinogen genes and bleeding risk in patients who received DOACs in South Korea. The study found that 2 genotypes were related to bleeding risk for DOACs and developed a risk scoring system to predict it.

Illustration by Xinyu Li

Incorporating assessment of fibrinogen gene polymorphisms and bleeding risk in patients treated with direct oral anticoagulants

Direct oral anticoagulants (DOACs) have become entrenched as the dominant anticoagulant over the last decade for patients with venous thrombosis and atrial fibrillation.1 Compared...

Promise and pitfalls of ChatGPT for patient education on coronary angiogram

The past decade has seen extraordinary and rapid progress in the field of artificial intelligence (AI), which produces computer systems capable of performing tasks...

Association between genetic polymorphisms in fibrinogen genes and bleeding risk in patients treated with direct oral anticoagulants

Direct oral anticoagulants (DOACs) are widely prescribed for the prevention and treatment of stroke, systemic embolism and venous thromboembolism.1 Their mechanism of action involves...

Effects of sex on clinical outcomes of hypertrophic cardiomyopathy in Singapore

Hypertrophic cardiomyopathy (HCM) is a common inherited cardiomyopathy.1 The phenotypic expression of HCM is highly diversified with varying extents of myocardial hypertrophy, which can...

Clinical outcomes of hospitalised individuals with spin-induced exertional rhabdomyolysis

Rhabdomyolysis is a clinical and biochemical syndrome caused by the breakdown of myocytes and release of intracellular components into the bloodstream.1 A subset of...

MOST CITED ARTICLES

Review on Epidemic of Obesity

Rationale for Redefining Obesity in Asians

MOST VIEWED ARTICLES

VOWELS: A communication framework for disclosing medical errors in medical oncology...

HLA-B*5801 testing: Is it time to consider mandatory testing prior to...